文献速递泌尿生殖PET

PSMA PET衍生参数与寡复发前列腺癌患者经转移灶导向治疗后的结局关联

Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer.
PubMed 文献 · Radiology · 2023-01-01

这项单中心II期试验的回顾性分析纳入74例生化复发前列腺癌患者,PSMA PET共检出145个病灶(86%为转移性淋巴结),测量及校正后的PSMA PET参数与转移灶导向治疗后生化进展风险降低相关(HR范围0.61-0.98)。

要点

  • PSMA PET检出145个病灶,其中125个(86%)为转移性淋巴结。
  • 应用校正因子后,145个病灶中88个(61%)的PSMA评分发生改变。
  • 测量及校正后的PSMA PET参数均与MDT后生化进展风险降低相关。

核心结论

  • 测量及校正后的PSMA PET参数与接受MDT的寡复发前列腺癌患者生化进展相关。

研究设计与样本

  • 单中心II期试验的回顾性分析,纳入74例经最大局部治疗后生化复发且常规影像无疾病证据的患者,2017年5月至2021年11月行PSMA PET,对发现的复发灶行MDT。

关键影像表现/征象

  • PSMA PET共检出145个病灶,其中125个(86%)为转移性淋巴结。
  • 记录复发灶的SUVmax、SUVmean及分别以2.5(SUVmean2.5)和41%(SUVmean41%)为阈值得出的PSMA肿瘤体积,并赋予分子影像PSMA评分。
  • 上述参数还针对平滑滤波和部分容积效应进行校正,并重新赋予PSMA评分。
  • 应用校正因子后,145个病灶中88个(61%)的PSMA评分发生改变。

诊断标准与关键数值

  • PSMA肿瘤体积分别以SUVmean2.5和SUVmean41%为阈值计算。
  • 未校正参数中,平均SUVmax、平均SUVmean2.5和平均SUVmean41%与较低的生化进展风险相关(HR范围0.77-0.95;95%CI:0.61, 1.00;P=.03至P=.04)。
  • 校正后参数中,平均SUVmax、平均SUVmean2.5、平均SUVmean41%、平均PSMA评分、最大SUVmean2.5、最大SUVmean41%和最大PSMA评分与较低的生化进展风险相关(HR 0.61-0.98;95%CI:0.39, 1.00;P=.01至P=.04)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Prostate-specific membrane antigen (PSMA) PET is useful in the early detection of oligorecurrent prostate cancer (PCa), but whether PSMA PET parameters can be used to identify patients who would benefit from metastasis-directed therapy (MDT) with radiation or surgery remains uncertain. Purpose To assess the association of PSMA PET parameters with outcomes of patients with oligorecurrent PCa after MDT. Materials and Methods In this retrospective analysis of a single-center phase II trial that enrolled patients with biochemical recurrence of PCa after maximal local therapy and with no evidence of disease at conventional imaging, patients underwent PSMA PET (between May 2017 and November 2021), and unveiled recurrences were treated with MDT. Maximum standardized uptake value (SUVmax) and mean standardized uptake value (SUVmean) and PSMA tumor volume derived using thresholds of 2.5 (SUVmean2.5) and 41% (SUVmean41%), respectively, were recorded for sites of recurrence on PSMA PET scans, and a molecular imaging PSMA score was assigned. These parameters were also corrected for smooth filter and partial volume effects, and the PSMA score was reassigned. Cox proportional hazards models were used to evaluate the relationship between PSMA PET parameters and outcomes. Results A total of 74 men (mean age, 68.3 years ± 6.6 [SD]) with biochemical recurrence of PCa were included. PSMA PET revealed 145 lesions in the entire cohort, of which 125 (86%) were metastatic lymph nodes. Application of the correction factor changed the PSMA score in 88 of 145 lesions (61%). Mean SUVmax, SUVmean2.5, and SUVmean41% were associated with lower risk of biochemical progression (hazard ratio [HR] range, 0.77-0.95; 95% CI: 0.61, 1.00; P = .03 to P = .04). For corrected parameters, mean SUVmax, mean SUVmean2.5, mean SUVmean41%, mean PSMA score, maximum SUVmean2.5, maximum SUVmean41%, and maximum PSMA score were associated with a lower risk of biochemical progression (HR, 0.61-0.98; 95% CI: 0.39, 1.00; P = .01 to P = .04). Conclusion Measured and corrected PSMA PET parameters were associated with biochemical progression in men with oligorecurrent PCa treated with MDT. Clinical trial registration no. NCT03160794 © RSNA, 2023 See also the editorial by Civelek in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Murad V, Glicksman RM, Berlin A, et al. Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer. Radiology. 2023. PMID: 38051188. doi:10.1148/radiol.231407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。